Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
6.49
-0.21 (-3.13%)
Bozor ochiq: Aug 12, 2026, 12:24 PM EDT
6.70
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 4:10 PM EDT
Eupraxia Pharmaceuticals Inc., klinik bosqichdagi biotexnologiya kompaniyasi, tibbiy ehtiyojlari qondirilmagan terapevtik sohalarni davolash uchun mahsulotlarni ishlab chiqishga qaratilgan. Uning patentlangan Diffusphere texnologiyasi tibbiy ehtiyojlari sezilarli darajada qondirilmagan qo'llanmalar uchun dori etkazib berishni optimallashtiradi. Kompaniyaning mahsulot portfeliga EP-104IAR, tizza osteoartritini davolash uchun III bosqich klinik sinovlarida; EP-104GI, eosinofilik ezofagitni davolash uchun II bosqich klinik sinovlarida; va EP-104, oshqozon-ichak trakti, masalan, eosinofilik ezofagitni davolash uchun preklinik tadqiqotlar ostida. Kompaniya ilgari Plaza Capital Partners Inc. nomi bilan tanilgan va 2012 yil may oyida Eupraxia Pharmaceuticals Inc. nomini o'zgartirgan. Eupraxia Pharmaceuticals Inc. 2011 yilda ro'yxatga olingan va uning shtab-kvartirasi Kanadaning Viktoriya shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. James A. Helliwell FRCPC, M.D. | CEO & Director |
| Dr. Jeffrey Millard Ph.d. | Executive Vice President of Technical Operations |
| Dr. Jeymi Tambiah M.S. | Chief Medical Officer |
| Mr. Alex Therien | Executive VP of R&D |
| Mr. Alexander John Rothwell Eng., M.B.A. | Chief Financial Officer |
| Mr. Paul Anthony Brennan B.Sc., M.Sc. | Chief Corporate Development Officer |
| Ms. Wajida Leclerc B.A., CCP, CHRP | Executive Vice President Corporate Services & People |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-06 | F-X | d41490dfx.htm |
| 2026-08-06 | F-10 | d142683df10.htm |
| 2026-07-15 | 6-K | f6k_071526.htm |
| 2026-07-13 | 6-K | f6k_071326.htm |
| 2026-07-07 | 6-K | f6k_070726.htm |
| 2026-06-22 | 6-K | f6k_062226.htm |
| 2026-05-29 | 6-K | f6k_052826.htm |
| 2026-05-28 | 6-K | f6k_052826.htm |
| 2026-05-12 | 6-K | d133809d6k.htm |
| 2026-05-06 | 6-K | f6k_050626.htm |